1 / 28

The Many Roles of Computational Science in Drug Design and Analysis

The Many Roles of Computational Science in Drug Design and Analysis. Mala L. Radhakrishnan Department of Chemistry, Wellesley College June 17, 2008 DOE CSGF Fellows Conference, Washington, D.C. …target rapidly mutates!. Amprenavir bound to HIV-1 protease. (HIV).

luyu
Télécharger la présentation

The Many Roles of Computational Science in Drug Design and Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Many Roles of Computational Science in Drug Design and Analysis Mala L. Radhakrishnan Department of Chemistry, Wellesley College June 17, 2008 DOE CSGF Fellows Conference, Washington, D.C.

  2. …target rapidly mutates! Amprenavir bound to HIV-1 protease (HIV) Shafer, Clinical Microbiology Rev., 15:247, 2002 Kim et al, J. Am . Chem . Soc. 117:1181, 1995

  3. HIV−1 Protease Understanding binding specificity and promiscuity Developing methods for optimal drug cocktail design Designing broadly-binding HIV-1 protease inhibitors

  4. Ligand (drug) Receptor (target) Goal: create a high-affinity interaction  low DG

  5. Ligand (drug) Receptor (target) “Reality”: Quantum mechanics Statistical Mechanics

  6. Ligand (drug) Receptor (target) Model: Atoms as spheres Point charges (Rigid Binding)

  7. - + - + + - Ligand (drug) Receptor (target) Model: Atoms as spheres Point charges (Rigid Binding)

  8. + + + + + + + + + + + + + + − − − − − − − − − − − − − − + + + + + + + + + + + + + + - + - + + - Drug Target Interactions with solvent

  9. + + + + + + + + − − − − − − − − + + + + + + + + - + - + + - Loss of solvation  FAVORS LOW CHARGE MAGNITUDES Drug-target interaction  FAVORS HIGH CHARGE MAGNITUDES

  10. Our Model - + - + + - “solvent continuum”: high dielectric + mobile ions

  11. Designing Toward Multiple Targets - + - + + - + ? + - - Physical Properties  Tailored Recognition +

  12. Solvent continuum + L R C Theoretical Framework DGbind = vdW + SASA + qLTLqL + qRTRqR + qRTCqL DG - - + + - - - - - - + … + - charge value + + + + + The binding profile looks like a paraboloid. Kangas and Tidor, J Chem Phys, 109:7522-7545, 1998

  13. Theoretical Framework A specific ligand A promiscuous ligand Radhakrishnan and Tidor, J. Phys. Chem. B, 111:13419-13435, 2007

  14. Model Systems Radhakrishnan and Tidor, J. Phys. Chem. B, 111:13419-13435, 2007

  15. Theory and Model Systems Agree: • Smaller ligands are more promiscuous than larger ligands Theory Numerical Experiment DG P3 qR black:small red: big Binding profile for a small ligand Binding profile for a big ligand Drug charge distribution

  16. Some Other Insights • Smaller ligands are more promiscuous • Hydrophobic ligands are more promiscuous because they are near the center of biological charge space • Hydrophobic ligands are more promiscuous because they are not as sensitive to shape differences • Flexibility makes polar and charged ligands more specific, but allows for greater overall binding affinity to multiple partners. • Asymmetric groups can lead to increased promiscuity Radhakrishnan and Tidor, J. Phys. Chem. B, 111:13419-13435, 2007

  17. HIV−1 Protease Understanding binding promiscuity Developing methods for optimal drug cocktail design Designing broadly-binding HIV-1 protease inhibitors

  18. Rational Cocktail Design Drug 1 decoy target variants Drug 2

  19. Cocktail Design as an Optimization Problem drugs drugs targets pre-process out decoys affinity thresholds E A’ A targets+decoys 1 0 0 0 1 1 ... (mxn) Minimize # drugs in cocktail All targets covered by at least one drug Minimize sum of binding energies All targets covered by at least one drug Size of cocktail is optimal Can also combinatorially design individual molecular members simultaneously

  20. Optimally covering model ensembles - - - - 0 0.5 0.5 -0.5 0 -0.5 0 0 Radhakrishnan and Tidor, J. Chem. Inf. Model . 48:1055-1073, 2008

  21. Tiling the Mutation Space q(target,2) q(target,2) q(target,1) q(target,1) 0 0 0 0 -0.5 0.5 0.5 -0.5 0 -0.5 0 -0.5 0 0.5 0 0.5 0.5 -0.5 -0.5 0.5

  22. HIV−1 Protease Understanding binding promiscuity Developing methods for optimal drug cocktail design Designing broadly-binding HIV-1 protease inhibitors

  23. Designing into Multiple Targets: HIV-protease Wild Type V82A I84V D30N L90M I50V L63P, V82T, I84V

  24. DG,High resolution energy function DG, fast energy function Methods: OH F F Functional groups Molecular “scaffolds” Dead-End Elimination, A*: List of tight-binding compounds Michael Altman et al.J. Amer. Chem Soc., 130: 6099-6113, 2008

  25. Design of Broadly−Binding HIV−1 Protease Inhibitors Wild Type V82A I84V D30N L90M I50V L63P, V82T, I84V 7 Size of optimal cocktail Physical Properties 0 0 7 Energy threshold (kcal/mol) Michael Altman et al.J. Amer. Chem Soc., 130: 6099-6113, 2008

  26. Summary • Physical Framework for Binding Promiscuity and Specificity • Methods For Designing Toward Target Ensembles • HIV-1 Protease as a Case Study

  27. The Many Roles of Computation Computation can… …map out key interactions in a binding site. …design drugs. …predict properties that make drugs specific or “promiscuous.” …design drug cocktails. …etc. ! …design novel experimental systems. …analyze clinical data …model cellular events.

  28. Acknowledgements MIT Wellesley • Bruce Tidor - Bilin Zhuang and Andrea Johnston • Michael Altman • Dave Czerwinski • Celia Schiffer, Tariq Rana, Michael Gilson and groups. Funding: DOE CSGF, NIH, Wellesley College

More Related